Drug Trial Radar · NCT05667623
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
270
Actual
Start
Feb 6, 2023
Primary completion
Jun 17, 2024
Study completion Nov 29, 2024
Sponsor
- Lead sponsor
- Otsuka Beijing Research InstituteOtsuka
- Sponsor type
- Industry
- First posted
- Dec 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.
Conditions
- Atopic Dermatitis (AD)
Interventions
1% OPA-15406 OintmentDrug
Twice-daily administration for 4 weeks/24 weeks.
0% OPA-15406 VehicleOther
Twice-daily administration for 4 weeks/24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success rate in Investigator's Global Assessment at Week 4Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.